Proje Geliştirme ve
Koordinasyon Birimi

2015-10-19 United Kingdom: The Development of Magnetic Nanocomplex for Drug Delivery and Remotely Controlled Local Toxicity in Tumor

The Development of Magnetic Nanocomplex for Drug Delivery and Remotely Controlled Local Toxicity in Tumor

Description of the project offered: 
The team: 
- Cavendish NanoTherapeutics Ltd., United Kingdom
- Cavendish Laboratory, University of Cambridge, United Kingdom
- National Cancer Institute, Ukraine
- Radmir Company, Ukraine
- Institute for Metal Physics, Ukraine
We have synthesized a smart magnetic nanocomplex and developed equipment for personalized combined cancer therapy. Its advantage is locally controlled by moderate inductive hyperthermia toxicity in tumor. The team conducted a successful pre-clinical and pilot clinical trials. We are looking for the partners for joint project for further development of the technology and equipment.

Description .
Magnetic nanoparticle hyperthermia appears well suited as an effective tumor therapy. However, there are a number of limitations of magnetic nanoparticle hyperthermia such as: (1) therapy by nanoparticles in the temperature range 43-70 °C can be accompanied by the formation of drug resistance due to the induction of heat shock proteins, (2) the temperature above 45 °C may shut down tumor tissue perfusion, and (3) targeted therapy with magnetic nanoparticles is often not suitable for disseminated and abdominal tumors.
To overcome these problems our team has developed the technology of magnetic nanotherapy which comprises: (1) the synthesis of nanocomplex with personalized magnetic properties for every cancer patient, (2) combined cancer therapy by nanocomplex in the temperature range of 37-40 °C, (3) remotely controlled local oxidative stress in tumor by external electromagnetic fields.
The key aim of the proposed project is to develop magnetically operated nanocomplex and equipment for innovative technology of personalized cancer magnetic nanotherapy, and economically sound transforming from the pre-clinical laboratory scale to clinical testing. 
Tumor treatment with magnetic nanocomplex is based on known facts:
(1) metal oxide nanoparticles and iron ions are acceptors of electromagnetic energy for its conversion to spin magnetochemical interactions in the metal centers,
(2) semiconductor materials ability, in particular metal oxide nanoparticles, to generate oxygen radicals and control oxidative stress in biological media by electromagnetic irradiation, and
(3) chemotherapy can influence on concentration in tumor tissue of ion iron and oxide radicals. 
The occurrence of these effects is dependent on similarities in the energetic states of the nanomaterials and ambient redox-active aqueous substances. Depending on the parameters of the synthesis it is possible to synthesize nanocomplex with certain magnetic properties. The value of magnetic moment and concentration of paramagnetic centers in nanocomplex is individual for each patient, depending on individual sensitivity to chemotherapy. The combined influence of inhomogeneous magnetic and electromagnetic fields during magnetic nanotherapy initiated splitting of electron energy levels in magnetic nanocomplex and unpaired electron transfer from iron oxide nanoparticles to anticancer drug and tumor cells. Our experiments in vitro and in vivo animal cancer models showed that nanocomplex induced greater antitumor effect and lesser side effects during magnetic nanotherapy of tumor as compared to conventional antitumor drug. Pilot clinical data demonstrate an average 15-20% increase of the efficacy of chemotherapy (survival rates and/or reduction in the size of tumors) of breast cancer patients.
Project proposer:   Valerii Orel ()
Partner role:  Project coordinator 
Partner organisation:  Small or medium-sized enterprise (SME)
Call for proposal identifier:  H2020-NMBP-2016-2017

Description of the collaboration sought: 
We are looking for a partner who
- owns the technology for synthesizing superparamagnetic nanoparticles
- is working in pharmacy 
Expertise sought: Medical biotechnology, Life sciences, Biotechnology, Medicine. Health, Industrial biotech, Nanotechnology and Nanosciences, 
Roles sought: Project coordinator, Project participant, 
Organisation types sought: Research, Industry, Small or medium-sized enterprise (SME), 
Countries sought: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom, Albania, Bosnia and Herzegovina, Croatia, Iceland, Israel, Liechtenstein, Macedonia, the former Yugoslav Republic of, Montenegro, Norway, Serbia, Switzerland, Turkey, 

Call for proposal specific information
The referenced call for proposals has no specific fields defined.